1,782 reports of this reaction
1.8% of all GLIPIZIDE TABLETS reports
#11 most reported adverse reaction
ASTHENIA is the #11 most commonly reported adverse reaction for GLIPIZIDE TABLETS, manufactured by ANI Pharmaceuticals, Inc.. There are 1,782 FDA adverse event reports linking GLIPIZIDE TABLETS to ASTHENIA. This represents approximately 1.8% of all 96,589 adverse event reports for this drug.
Patients taking GLIPIZIDE TABLETS who experience asthenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHENIA is a less commonly reported adverse event for GLIPIZIDE TABLETS, but still significant enough to appear in the safety profile.
In addition to asthenia, the following adverse reactions have been reported for GLIPIZIDE TABLETS:
The following drugs have also been linked to asthenia in FDA adverse event reports:
ASTHENIA has been reported as an adverse event in 1,782 FDA reports for GLIPIZIDE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHENIA accounts for approximately 1.8% of all adverse event reports for GLIPIZIDE TABLETS, making it a notable side effect.
If you experience asthenia while taking GLIPIZIDE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.